“Bacteriostatic water” is often treated as if it were a complete product specification. It is not.
An official U.S. label for Bacteriostatic Water for Injection, USP describes a specific sterile, nonpyrogenic finished drug containing water for injection and 0.9% benzyl alcohol in a multiple-dose container.[1][2] Each of those words has a defined, product-specific context.
The presence of a preservative does not by itself prove sterility. A clear solution does not prove identity, endotoxin control, or container integrity. An FDA label for one manufacturer’s finished product does not validate a separate 3 mL vial.
This page explains what evidence belongs behind the name. It intentionally does not provide preparation, mixing, reconstitution, administration, storage, or self-use instructions.
Evidence state at a glance
| Field | Official reference-product context |
|---|---|
| Established name in the referenced label | Bacteriostatic Water for Injection, USP |
| Referenced preservative | Benzyl alcohol, 0.9% or 9 mg/mL |
| Referenced container type | Multiple-dose container |
| FDA application identified | NDA 018802 |
| Key quality attributes | Identity, composition, sterility assurance, endotoxin/pyrogen control, particulate control, preservative content, container closure, and stability |
| Clinical-evidence role | None; this is a finished-material identity and quality topic |
| Catalog status | 3 mL product’s source identity and sterility evidence unresolved |
| Evidence reviewed | August 27, 2026 |
What does the official name mean?
The DailyMed label linked below identifies a finished drug with a particular composition, manufacturer chain, container, NDC source, and application status.[1] FDA’s multi-application approval correspondence lists Bacteriostatic Water for Injection, USP under NDA 018802/S-042.[2] The PDF is filed under 018892, which explains its container filename; that filename does not reassign the bacteriostatic-water application.
The full established name should not be shortened into a quality assumption:
- Water for Injection identifies a compendial water context, not ordinary purified or laboratory water.
- Bacteriostatic refers to an antimicrobial preservative system under defined conditions.
- Sterile and nonpyrogenic are separate finished-product quality claims.
- USP refers to conformance with applicable compendial standards; it is not a decorative synonym for “high quality.”
- Multiple-dose container is a labeled container classification, not evidence that any unlabeled vial has the same design or performance.
The shorthand name does not establish that formulation. The exact preservative concentration, source label, and application therefore matter.
Bacteriostatic does not mean sterile
Benzyl alcohol can limit microbial growth under defined conditions. It does not create a blanket guarantee that a vial was manufactured aseptically, remains sterile, contains an acceptable endotoxin level, or has an intact container closure.
FDA’s aseptic-processing guidance describes sterility assurance as a manufacturing and quality system. It includes facility and equipment design, process control, personnel practices, environmental monitoring, validation, and quality oversight.[4]
FDA’s specifications guidance separately identifies sterility, endotoxin or pyrogen testing, particulate matter, and other product-specific controls for parenteral products.[5] FDA’s 2026 endotoxin update also emphasizes that a selected test method must be shown suitable for the actual material or product.[6]
No single test replaces the whole system. For example:
- a benzyl-alcohol assay does not establish sterility;
- a sterility test does not quantify preservative content;
- a clear visual appearance does not establish endotoxin control;
- a generic certificate does not prove container-closure integrity or stability;
- a valid result for one lot does not automatically describe another lot.
Preservative amount and antimicrobial performance
Karabit and colleagues' 1986 paper examined benzyl alcohol using a kinetic approach. The indexed abstract identifies five test organisms and examines temperature, pH and concentration-related behavior. It describes antimicrobial characterization, not a clinical trial or verification of a current commercial vial. Only the public abstract was used for this appraisal; it does not supply the numerical results needed to reconstruct organism-specific performance. Primary indexed abstract, PMID 3531242.
An analytical result about benzyl alcohol concentration concerns the amount measured in the submitted sample. An antimicrobial effectiveness assessment concerns biological performance under a defined challenge. A claim about the first is not automatically a result for the second.
FDA's manufacturing questions and answers explicitly distinguish preservative effectiveness testing from analytical testing of preservative content. This is an official quality framework, not a numerical performance result for Serum Research's catalog material. FDA production and process controls, question 21.
Benzyl alcohol safety history and its limits
CDC's 1982 report described 16 neonatal deaths at two centers thought to be associated with benzyl alcohol exposure. The implicated flushes were bacteriostatic normal saline. The report described severe illness and stated that similar deaths were not seen after a change to preservative-free flushes. This was an investigation of a clinical cluster, not a randomized safety comparison. CDC surveillance report.
The reviewed bacteriostatic water label contraindicates neonatal use because of benzyl alcohol toxicity. It also contains other restrictions that depend on the intended route and use. This article does not reproduce administration instructions or derive an alternative exposure threshold. Current accessed reference label.
The historical cases and the label answer related but different questions. The cases explain an important observed harm signal in a vulnerable clinical population. The label states boundaries for a specified pharmaceutical product. Neither authenticates the composition of a research-market vial.
A directory identifier does not authenticate a vial
FDA's National Drug Code Directory includes information on approved and unapproved finished products, as well as repackaged or relabeled products. FDA explicitly states that an NDC or directory entry does not itself establish approval or that the agency has verified the submitted information. FDA National Drug Code Directory explanation.
A pharmaceutical label can accurately describe a product without describing the vial in a separate research catalog. An article must establish the connection rather than assume it from a similar name or preservative percentage. The source may be authentic while the comparison remains unsupported.
Container integrity and stability are product-specific
FDA's container-closure guidance treats integrity testing as a product-and-package-specific question. It calls for validated methods appropriate to the system being evaluated and explains that a preservative can complicate microbial assessment. The guidance concerns evidence supporting pharmaceutical stability; it is not a consumer method for extending a vial's usable life. FDA container and closure integrity guidance.
This has an immediate implication for research summaries. A study of one closure design does not automatically cover a different stopper, seal or container. The same liquid name does not erase those differences. If the underlying report does not identify the package, a reader cannot assess how closely the result matches the product under discussion.
For the same reason, an unopened product's expiration date should not be copied into an article as proof of a different preparation's stability. The article would be changing the tested material and conditions while retaining the original conclusion. That is an unsupported extrapolation, not a conservative reading of the evidence.
What should a useful lot record contain?
A meaningful quality record connects the result to the exact product and lot. Depending on the claims made, it should identify:
- established product name and formulation;
- source manufacturer and manufacturing site where applicable;
- NDC/application or an explicit non-drug research-material status;
- lot number, fill, container, closure, and expiration or retest date;
- identity and preservative-content method, acceptance criterion, and result;
- sterility and endotoxin methods, criteria, and results when those attributes are claimed;
- pH, particulate, appearance, and other applicable release tests;
- laboratory identity, report number, dates, and accountable approval.
The record should also make clear what was not tested. “Pass” without a method, criterion, result, and lot linkage is not enough.
A recall shows why lot assurance is separate
In 2019, FDA posted a recall of one lot of an approved Bacteriostatic Water for Injection, USP product because sterility assurance could not be confirmed.[3]
That recall does not say anything about the Serum Research vial. It demonstrates a general quality principle: even an established product name and valid approved label do not remove the need for lot and process controls.
Why ClinicalTrials.gov does not answer this question
Trial protocols may mention bacteriostatic water as a diluent, comparator, or supporting material. A protocol mention does not evaluate the water as a treatment and does not prove that a commercial vial matches the protocol material.
The appropriate evidence for this page is therefore product identity, approval status, manufacturing assurance, and lot-specific release documentation, not a list of health studies.
Why the catalog product is not linked
The Serum Research record says its 3 mL vial is sterile bacteriostatic water containing 0.9% benzyl alcohol. The public page does not identify the source manufacturer, NDC/application, source finished-product label, lot, expiration, container-closure record, or quality report supporting those claims.
Before a link is added, the business must establish whether the item is:
- an intact approved finished drug;
- a repackaged or relabeled finished drug;
- a separately manufactured research material;
- or another product category.
That decision changes which name, claims, records, and regulatory statements are accurate. Until it is resolved, the knowledge page should not endorse the 3 mL item or repeat its sterility claim.
Major evidence limitations
- A preservative limits growth under specified conditions; it does not independently establish sterility.
- The referenced 0.9% composition and NDA belong to a specific finished product.
- Product appearance cannot establish identity, endotoxin state, sterility, or container integrity.
- One analytical result cannot cover every quality attribute.
- Trial mentions do not validate a commercial support material.
- No source reviewed for this page establishes equivalence between the referenced NDA product and the Serum Research vial.
Frequently asked questions
Is bacteriostatic water the same as sterile water?
No. The referenced bacteriostatic product contains an antimicrobial preservative. Other sterile-water products may not. Exact names and labels should remain distinct.
Does benzyl alcohol make a product sterile?
No. Preservative content and sterility are separate quality attributes supported by different controls.
Is every bacteriostatic-water product 0.9% benzyl alcohol?
No universal conclusion should be drawn from a shorthand name. The exact finished-product label determines the preservative and concentration.
Does an NDA label validate a repackaged or research vial?
No. Source identity, packaging history, manufacturer, container closure, lot, and matching records still must be established.
Why does this page not include mixing or reconstitution directions?
Because this is an identity and quality guide. Preparation and administration information is product- and protocol-specific and is outside the page’s scope.
Does this page validate Serum Research BAC Water?
No. Its source finished-product identity, composition, sterility assurance, and lot evidence remain unresolved.
Primary and official sources
- DailyMed Bacteriostatic Water for Injection, USP label
- FDA multi-application approval correspondence listing NDA 018802/S-042 for Bacteriostatic Water for Injection, USP
- FDA-posted 2019 recall for potential lack of sterility assurance
- FDA aseptic-processing CGMP guidance
- FDA/ICH Q6A specifications guidance
- FDA clarification on pyrogen and endotoxin testing, 2026
Further research appraisals
Prepared for Serum Research, a commercial supplier. These research summaries do not independently validate its catalog products and are not instructions for personal medical use.